Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model
Tóm tắt
Cirrhosis is a long-term consequence of chronic hepatic injury with fibrosis. No effective therapy is currently available for decompensated cirrhosis except liver transplantation. Hence, we investigated the effect of bone marrow-derived mesenchymal stem cells (BM-MSCs) on hepatic fibrosis in a thioacetamide (TAA)-induced cirrhotic rat model. The BM-MSCs were injected directly into the right liver lobe twice, at 6 and 8 weeks during the 12-week TAA administration, in thioacetamide (TAA)-induced cirrhotic rats model, and hepatic fibrosis was evaluated. At 12 weeks, the effect of BM-MSCs on hepatic fibrosis was analyzed histomorphologically using the Laennec fibrosis scoring system, and the collagen proportionate area was quantified. Cirrhosis-related factors, such as transforming growth factor β1 (TGF-β1), type 1 collagen (collagen-1), α-smooth muscle actin (α-SMA), and P-Smad3/Smad3 expression levels, were evaluated using real-time polymerase chain reaction and western blot assays. According to the Laennec fibrosis scoring system, histological improvement was observed in hepatic fibrosis after BM-MSC treatment (P <0.01). The percentage of the collagen proportionate area decreased from 16.72 ± 5.51 to 5.06 ± 1.27 after BM-MSC treatment (P <0.01). The content of hepatic hydroxyproline was significantly lower in the BM-MSC treated group (46.25 ± 13.19) compared to the untreated cirrhotic group (85.81 ± 17.62; P <0.01). BM-MSC administration significantly decreased TGF-β1, collagen-1, and α-SMA expression in TAA-induced cirrhotic rats (P <0.01). We also confirmed P-Smad3/Smad3, downstream effectors of the TGF-β1 signaling pathway, and found that MSC transplantation inhibited Smad3 phosphorylation. BM-MSC treatment attenuated hepatic fibrosis in rats with TAA-induced cirrhosis, raising the possibility of the clinical use of BM-MSCs in the treatment of cirrhosis.
Tài liệu tham khảo
Bolondi L, Gramantieri L: From liver cirrhosis to HCC. Intern Emerg Med. 2011, 6 (Suppl 1): 93-98. 10.1007/s11739-011-0682-8.
Iredale JP: Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ. 2003, 327 (7407): 143-147. 10.1136/bmj.327.7407.143.
Kim MY, Baik SK, Yea CJ, Lee IY, Kim HJ, Park KW, Kim HK, Suk KT, Kim JW, Kim HS, Kwon SO, Cha SH, Kim YJ, Koh SB, Chang SJ: Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009, 21 (11): 1241-1246. 10.1097/MEG.0b013e32832a21c1.
Kim MY, Suk KT, Baik SK, Kim HA, Kim YJ, Cha SH, Kwak HR, Cho MY, Park HJ, Jeon HK, Park SY, Kim BR, Hong JH, Jo KW, Kim JW, Kim HS, Kwon SO, Chang SJ, Baik GH, Kim DJ: Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology. 2012, 56 (3): 1053-1062. 10.1002/hep.25752.
Lee SS, Shin HS, Kim HJ, Lee SJ, Lee HS, Hyun KH, Kim YH, Kwon BW, Han JH, Choi H, Kim BH, Lee JH, Kang HY, Shin HD, Song IH: Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol. 2012, 18 (1): 48-55. 10.3350/kjhep.2012.18.1.48.
Moon KM, Kim G, Baik SK, Choi E, Kim MY, Kim HA, Cho MY, Shin SY, Kim JM, Park HJ, Kwon SO, Eom YW: Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis. Clin Mol Hepatol. 2013, 19 (4): 389-398. 10.3350/cmh.2013.19.4.389.
Singal AK, Duchini A: Liver transplantation in acute alcoholic hepatitis: Current status and future development. World J Hepatol. 2011, 3 (8): 215-218. 10.4254/wjh.v3.i8.215.
Strom SC, Bruzzone P, Cai H, Ellis E, Lehmann T, Mitamura K, Miki T: Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant. 2006, 15 (Suppl 1): S105-S110. 10.3727/000000006783982395.
Strom S, Fisher R: Hepatocyte transplantation: new possibilities for therapy. Gastroenterology. 2003, 124 (2): 568-571. 10.1053/gast.2003.50072.
Kakinuma S, Nakauchi H, Watanabe M: Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. J Gastroenterol. 2009, 44 (3): 167-172. 10.1007/s00535-008-2297-z.
Kharaziha P, Hellstrom PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, Telkabadi M, Atashi A, Honardoost M, Zali MR, Soleimani M: Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009, 21 (10): 1199-1205. 10.1097/MEG.0b013e32832a1f6c.
Cho KA, Lim GW, Joo SY, Woo SY, Seoh JY, Cho SJ, Han HS, Ryu KH: Transplantation of bone marrow cells reduces CCl4 -induced liver fibrosis in mice. Liver int. 2011, 31 (7): 932-939. 10.1111/j.1478-3231.2010.02364.x.
Sakaida I, Terai S, Yamamoto N, Aoyama K, Ishikawa T, Nishina H, Okita K: Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology. 2004, 40 (6): 1304-1311. 10.1002/hep.20452.
Hardjo M, Miyazaki M, Sakaguchi M, Masaka T, Ibrahim S, Kataoka K, Huh NH: Suppression of carbon tetrachloride-induced liver fibrosis by transplantation of a clonal mesenchymal stem cell line derived from rat bone marrow. Cell Transplant. 2009, 18 (1): 89-99. 10.3727/096368909788237140.
Higashiyama R, Inagaki Y, Hong YY, Kushida M, Nakao S, Niioka M, Watanabe T, Okano H, Matsuzaki Y, Shiota G, Okazaki I: Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology. 2007, 45 (1): 213-222. 10.1002/hep.21477.
Mormone E, George J, Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 2011, 193 (3): 225-231. 10.1016/j.cbi.2011.07.001.
Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, Levicar N, Tait P, Scott M, Marley SB, Jestice K, Glibetic M, Bansi D, Khan SA, Kyriakou D, Rountas C, Thillainayagam A, Nicholls JP, Jensen S, Apperley JF, Gordon MY, Habib NA: Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008, 103 (8): 1952-1958. 10.1111/j.1572-0241.2008.01993.x.
Rockey DC: Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis. 2008, 12 (4): 939-962. 10.1016/j.cld.2008.07.011. xi
Sakaida I, Terai S, Nishina H, Okita K: Development of cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol. 2005, 38 (4): 197-202. 10.1007/s00795-005-0298-z.
Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I: Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells. 2006, 24 (10): 2292-2298. 10.1634/stemcells.2005-0542.
am Esch JS, Knoefel WT, Klein M, Ghodsizad A, Fuerst G, Poll LW, Piechaczek C, Burchardt ER, Feifel N, Stoldt V, Stockschläder M, Stoecklein N, Tustas RY, Eisenberger CF, Peiper M, Häussinger D, Hosch SB: Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells. 2005, 23 (4): 463-470. 10.1634/stemcells.2004-0283.
van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, Yarmush ML: Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2008, 47 (5): 1634-1643. 10.1002/hep.22236.
Sun CK, Chen CH, Kao YH, Yuen CM, Sheu JJ, Lee FY, Chen YT, Kung CT, Yip HK: Bone marrow cells reduce fibrogenesis and enhance regeneration in fibrotic rat liver. J Surg Res. 2011, 169 (1): e15-e26. 10.1016/j.jss.2010.03.023.
Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W: Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2013, 22 (6): 845-854. 10.1089/scd.2012.0395.
Gressner AM, Weiskirchen R: Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med. 2006, 10 (1): 76-99. 10.1111/j.1582-4934.2006.tb00292.x.
Dooley S, ten Dijke P: TGF-beta in progression of liver disease. Cell Tissue Res. 2012, 347 (1): 245-256. 10.1007/s00441-011-1246-y.
Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008, 134 (6): 1655-1669. 10.1053/j.gastro.2008.03.003.
Inagaki Y, Higashiyama R, Higashi K: Novel anti-fibrotic modalities for liver fibrosis: molecular targeting and regenerative medicine in fibrosis therapy. J Gastroenterol Hepatol. 2012, 27 (Suppl 2): 85-88. 10.1111/j.1440-1746.2011.07006.x.
Rosenbloom J, Mendoza FA, Jimenez SA: Strategies for anti-fibrotic therapies. Biochim Biophys Acta. 2013, 1832 (7): 1088-1103. 10.1016/j.bbadis.2012.12.007.
Atoui R, Shum-Tim D, Chiu RC: Myocardial regenerative therapy: immunologic basis for the potential "universal donor cells". Ann Thorac Surg. 2008, 86 (1): 327-334. 10.1016/j.athoracsur.2008.03.038.
Le Blanc K, Ringden O: Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med. 2007, 262 (5): 509-525. 10.1111/j.1365-2796.2007.01844.x.
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002, 99 (10): 3838-3843. 10.1182/blood.V99.10.3838.
Hu Y, Liao L, Wang Q, Ma L, Ma G, Jiang X, Zhao RC: Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med. 2003, 141 (5): 342-349. 10.1016/S0022-2143(03)00022-2.
Martin JY, Dean DD, Cochran DL, Simpson J, Boyan BD, Schwartz Z: Proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63) cultured on previously used titanium surfaces. Clin Oral Implants Res. 1996, 7 (1): 27-37. 10.1034/j.1600-0501.1996.070104.x.
Kim MY, Cho MY, Baik SK, Park HJ, Jeon HK, Im CK, Won CS, Kim JW, Kim HS, Kwon SO, Eom MS, Cha SH, Kim YJ, Chang SJ, Lee SS: Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol. 2011, 55 (5): 1004-1009. 10.1016/j.jhep.2011.02.012.
Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, Maimone S, Pleguezuelo M, Xirouchakis I, Guerrini GP, Patch D, Yu D, O'Beirne J, Dhillon AP: Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology. 2009, 49 (4): 1236-1244. 10.1002/hep.22745.
Abdel Aziz MT, Atta HM, Mahfouz S, Fouad HH, Roshdy NK, Ahmed HH, Rashed LA, Sabry D, Hassouna AA, Hasan NM: Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem. 2007, 40 (12): 893-899. 10.1016/j.clinbiochem.2007.04.017.
Li X, Benjamin IS, Alexander B: Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol. 2002, 36 (4): 488-493. 10.1016/S0168-8278(02)00011-9.
Tsukamoto H, Matsuoka M, French SW: Experimental models of hepatic fibrosis: a review. Semin Liver Dis. 1990, 10 (1): 56-65. 10.1055/s-2008-1040457.
Wrana JL: Transforming growth factor-beta signaling and cirrhosis. Hepatology. 1999, 29 (6): 1909-1910. 10.1002/hep.510290641.
Friedman SL: Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med. 1993, 328 (25): 1828-1835. 10.1056/NEJM199306243282508.
Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, Odell MM, Bauer RL, Ren HP, Haugen HS, Yeh MM, Fausto N: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2005, 102 (9): 3389-3394. 10.1073/pnas.0409722102.
Inagaki Y, Okazaki I: Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut. 2007, 56 (2): 284-292. 10.1136/gut.2005.088690.